BioProcess International is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Laurie Glimcher President & CEO at Dana Farber Cancer Institute

Profile

Laurie H. Glimcher, MD is the President and CEO of the Dana-Farber Cancer Institute, Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. Dr. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research.

She is a Member of the National Academy of Sciences, Fellow of the American Academy of Arts and Sciences, a Member of the National Academy of Medicine and the former President of the American Association of Immunologists. She is a member of the Cancer Research Institute, Prix Galien, Parker Institute for Cancer Immunotherapy, Repare Therapeutics, Abpro Therapeutics and Kaleido BioSciences, Inc. Scientific Advisory Boards, the Lasker Award Jury, the American Association for Cancer Research, Association of American Cancer Institutes, and the American Society of Clinical Oncology. She is the co-founder of Quentis Therapeutics. She previously served on the Board of Directors of Bristol-Myers Squibb Pharmaceutical Corporation and is currently on the Corporate Board of Directors of GlaxoSmithKline Pharmaceutical Corporation and the Waters Corporation.

A trailblazer in cancer research, Dr. Glimcher is celebrated for her research discoveries immunology, critical for both the development of protective immunity and for the pathophysiologic immune responses underlying autoimmune, infectious and malignant diseases. Dr. Glimcher speaks nationally and internationally on cancer, immunology, and translational medicine and has contributed more than 350 scholarly articles and papers to the medical literature.

Aside from her research efforts, Dr. Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science. Notably, she was the first female to be appointed as dean of Weill Cornell Medicine in New York and is the first female President and Chief Executive Officer of Dana-Farber Cancer Institute in Boston.

Agenda Sessions